Stockscreener 앱 받기
6.17
3.70%
0.22
시간 외 거래:
6.05
-0.12
-1.94%
전일 마감가:
$5.95
열려 있는:
$5.965
하루 거래량:
1.75M
Relative Volume:
0.99
시가총액:
$908.22M
수익:
$8.37M
순이익/손실:
$-69.66M
주가수익비율:
-11.01
EPS:
-0.5604
순현금흐름:
$-51.45M
1주 성능:
+2.66%
1개월 성능:
+3.18%
6개월 성능:
+99.03%
1년 성능:
+198.07%
1일 변동 폭
$5.87
$6.195
1주일 범위
$5.845
$6.27
52주 변동 폭
$1.74
$6.5999
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
명칭
Aclaris Therapeutics Inc
전화
484-324-7933
주소
701 LEE ROAD, WAYNE, PA
Compare ACRS vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ACRS
Aclaris Therapeutics Inc
|
6.17 | 931.77M | 8.37M | -69.66M | -51.45M | -0.5604 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-16 | 개시 | Oppenheimer | Outperform |
| 2025-07-10 | 재개 | Piper Sandler | Overweight |
| 2025-05-28 | 개시 | Wedbush | Outperform |
| 2025-03-18 | 재개 | Cantor Fitzgerald | Overweight |
| 2024-12-23 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2024-11-20 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-19 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2024-11-19 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-11-19 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-11-18 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-01-22 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-11-13 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-10-03 | 개시 | Evercore ISI | Outperform |
| 2022-12-14 | 개시 | Stifel | Buy |
| 2022-12-01 | 개시 | Goldman | Buy |
| 2022-10-06 | 개시 | BTIG Research | Buy |
| 2021-07-23 | 재개 | Jefferies | Buy |
| 2021-06-15 | 개시 | Piper Sandler | Overweight |
| 2021-04-21 | 개시 | H.C. Wainwright | Buy |
| 2019-10-22 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-06 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-27 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2019-05-06 | 개시 | SVB Leerink | Outperform |
| 2018-03-28 | 재개 | Leerink Partners | Outperform |
| 2018-02-09 | 개시 | Guggenheim | Buy |
| 2017-06-16 | 개시 | Cantor Fitzgerald | Overweight |
| 2016-11-29 | 개시 | Leerink Partners | Outperform |
| 2016-09-30 | 개시 | JMP Securities | Mkt Outperform |
| 2016-06-10 | 개시 | Guggenheim | Buy |
| 2015-11-02 | 개시 | Citigroup | Buy |
| 2015-11-02 | 개시 | Jefferies | Buy |
모두보기
Aclaris Therapeutics Inc 주식(ACRS)의 최신 뉴스
ETFs Investing in Aclaris Therapeutics, Inc. Stocks - TradingView
Aclaris Therapeutics (NASDAQ:ACRS) Stock: What Comes Next? - Kalkine Media
Aclaris Therapeutics (NASDAQ:ACRS) Trading 4.7% HigherWhat's Next? - MarketBeat
Aclaris Therapeutics (ACRS) Edges Lower by 1.37% as Shares Test Key Technical FloorRevenue Growth Stocks - vinanet.vn
Sei Investments Co. Makes New Investment in Aclaris Therapeutics, Inc. $ACRS - MarketBeat
Dimensional Fund Advisors LP Has $1.91 Million Stock Position in Aclaris Therapeutics, Inc. $ACRS - MarketBeat
FDA Fast Track Status Advances Aclaris Lichen Planus Drug - MyChesCo
HC Wainwright Has Pessimistic Outlook of ACRS Q3 Earnings - MarketBeat
Renaissance Technologies LLC Has $1.89 Million Stake in Aclaris Therapeutics, Inc. $ACRS - MarketBeat
Aclaris Therapeutics, Inc. (ACRS) stock price, news, quote and history - Yahoo Finance Australia
Aclaris Raises Capital as Drug Pipeline Spending Accelerates - MyChesCo
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Average Rating of "Buy" by Brokerages - MarketBeat
Aclaris Therapeutics, Inc. (ACRS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Wall Street Analysts Believe Aclaris (ACRS) Could Rally 69.2%: Here's is How to Trade - Zacks Investment Research
Weekly Recap: Q2 loss, runway into 2028 and Fast Track for modzatinib - TradingView
H.C. Wainwright Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Aclaris Therapeutics (ACRS) Stock Drifts Lower As Losses Deepen On Thin Revenue - simplywall.st
Aclaris Updates At-The-Market Equity Sales Agreement - The Globe and Mail
Aclaris Therapeutics (NASDAQ:ACRS) Stock Price Down 6%Here's What Happened - MarketBeat
US FDA Fast-tracks Aclaris’ Modzatinib for Lichen Planus - The Dermatology Digest
FDA grants fast track status to Aclaris’ lichen planus drug By Investing.com - Investing.com Nigeria
Craig-Hallum Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Aclaris Therapeutics Inc (8AT.MU) Analyst insights, Price targets and Recommendations - Yahoo Finance Australia
Aclaris Therapeutics (NASDAQ:ACRS) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS - MarketBeat
Aclaris Therapeutics (ACRS) Releases Q2 2026 Earnings: Revenue Declines, Losses Narrow - Quiver Quantitative
FDA grants fast track status to Aclaris’ lichen planus drug - Investing.com
Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP) - Yahoo Finance
Aclaris Therapeutics (NASDAQ: ACRS) widens loss as R&D spending accelerates - Stock Titan
Form 8K Aclaris Therapeutics Inc For: 6 August By Investing.com - Investing.com South Africa
Aclaris Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates - finance.yahoo.com
Earnings Flash (ACRS) Aclaris Therapeutics, Inc. Reports Q2 Revenue $1.6M, vs. FactSet Est of $1.4M - marketscreener.com
Earnings Flash (ACRS) Aclaris Therapeutics Posts Q2 Net Loss $0.15 a Share, vs. FactSet Est of $0.16 Loss - marketscreener.com
Aclaris Therapeutics reports Q2 2026 net loss of $21.5M, cash runway through 2028 - TradingView
ACRS: Higher net loss and R&D spend offset by strong cash reserves and major clinical milestones ahead - TradingView
Aclaris Therapeutics Inc earnings beat by $0.01, revenue topped estimates - Investing.com
Aclaris Therapeutics Q2 revenue beats analyst estimates - TradingView
BRIEF-Aclaris Therapeutics Q2 Net Income USD -21.505 Million Vs. IBES Estimate USD -21.3 Million - TradingView
Aclaris Therapeutics 2Q Loss/Shr 15c >ACRS - moomoo.com
Aclaris Therapeutics (NASDAQ: ACRS) CSO gets shares, some withheld - Stock Titan
Aclaris Therapeutics (NASDAQ:ACRS) Sets New 1-Year HighStill a Buy? - MarketBeat
Aclaris Therapeutics Inc expected to post a loss of 16 cents a shareEarnings Preview - TradingView
Vivo Capital LLC Sells 2,222,222 Shares of Aclaris Therapeutics, Inc. $ACRS - MarketBeat
Aclaris Therapeutics (ACRS) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Aclaris Therapeutics Inc (ACRS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Aclaris Therapeutics Inc (ACRS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Aclaris Therapeutics Inc (ACRS) Cash Flow - TradingKey
Kalehua Capital Management LLC Makes New $6.87 Million Investment in Aclaris Therapeutics, Inc. $ACRS - MarketBeat
Aclaris Therapeutics Inc (ACRS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ACRS|Aclaris Therapeutics Inc|Price:5.380|Chg%:+0.150 - TradingKey
Bollard Group LLC Reduces Position in Aclaris Therapeutics, Inc. $ACRS - MarketBeat
Aclaris Therapeutics Inc (ACRS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.86%
0.31%
자본화:
|
볼륨(24시간):